Manish A. Shah, MD, medical oncology, NewYork-Presbyterian/Weill Cornell, discusses the results of the METGastric study.
Manish A. Shah, MD, medical oncology, NewYork-Presbyterian/Weill Cornell, discusses the results of the METGastric study.
While the MET pathway is significant in predicting gastrointestinal (GI) cancers, it is a redundant pathway, said Shah. There are many ways to activate the pathways and increase pro-survival signaling, such as through EGFR, HER2 or IGFR, according to Shah.
Leveraging ctDNA to Predict Response in Patients With Myeloma Receiving CAR T Cells
March 20th 2023In an interview with Targeted Oncology, Hitomi Hosoya, MD, discussed the potential use of ctDNA in the myeloma space, including its ability to sequence BCMA-targeted therapies and reduce the need for bone marrow exams.
Read More
Molecular Targets Making Headway in Pediatric Thyroid Cancer Research
March 16th 2023In an interview with Targeted Oncology, Aime T. Franco, PhD, discussed the molecular landscape of pediatric patients with thyroid cancer and the presentation she gave at the 91st Annual Meeting of the American Thyroid Association.
Read More
2 Clarke Drive
Cranbury, NJ 08512